Treating Parkinson's Disease with Velvet Beans

In the quest to manage Parkinson's disease, the dietary approach has gained attention, particularly through the use of velvet beans. This article explores how certain beans may contribute to the treatment of Parkinson's, a condition characterized by tremors and movement difficulties, as first described in James Parkinson's Essay on the Shaking Palsy over two centuries ago.

The Dopamine Connection

Parkinson's disease is primarily linked to a deficiency of dopamine in the brain. While dopamine itself cannot cross the blood-brain barrier, its precursor, L-DOPA (levodopa), can enter the brain and be converted into dopamine by an enzyme called decarboxylase. This creates a challenge for treatment, as L-DOPA must reach the brain before it is converted. Conventional therapy uses L-DOPA in pill form, often combined with a decarboxylase inhibitor to maximize its effectiveness.

Velvet Beans as a Natural Source of L-DOPA

Historically, an Indian physician proposed velvet beans as a treatment for tremors long before the discovery of L-DOPA. Velvet beans are known to contain the highest concentration of L-DOPA among plants. In regions where access to conventional L-DOPA is limited due to cost, such as rural Africa, powdered velvet beans are often used as an alternative.

Clinical Evidence for Velvet Beans

Recent studies have begun to investigate the efficacy of velvet beans as a treatment option for Parkinson's disease. A randomized, double-blind clinical study showed that a dose of 30g (approximately three tablespoons) of velvet bean powder resulted in significant antiparkinsonian effects, often outpacing the effects of traditional medication in terms of speed and duration. Another study indicated that L-DOPA from velvet beans may be 2–3 times more potent than pill-form L-DOPA.

Long-term Use and Efficacy

In a follow-up study involving 14 patients, those taking roasted velvet bean powder demonstrated comparable efficacy to standard L-DOPA treatments over several months. Notably, one patient showcased remarkable improvement after being treated solely with velvet bean powder for 14 years.

Considerations and Limitations

Despite the promising results, there are important considerations regarding the use of velvet beans. Firstly, the taste of velvet bean powder is often reported as unpleasant, and the long-term data on its safety and efficacy remain limited. In high-income countries, while some may prefer natural therapies, researchers advise against substituting velvet beans for L-DOPA, which should remain the first-line treatment.

Quality Control Issues

Quality control is another concern. A study found that many velvet bean products available online do not contain the advertised amounts of L-DOPA, with some brands showing discrepancies of less than 10% of the claimed levels.

Exploring Fava Beans

Interestingly, fava beans (or broad beans) were the original source of L-DOPA discovered in 1913. Although they contain about 10 times less L-DOPA than velvet beans, they can be consumed in larger quantities as whole foods. Clinical trials have indicated that fava beans may provide similar benefits to traditional L-DOPA medications.

Potential Benefits of Fava Beans

Patients consuming fava beans demonstrated substantial clinical improvement, comparable to those receiving standard L-DOPA treatments. Fava beans not only provide L-DOPA but may also contain compounds that enhance its absorption and effectiveness.

Final Thoughts

While velvet beans and fava beans present intriguing alternatives to traditional Parkinson’s treatments, they are not without risks, including potential interactions with medications and conditions like favism, a genetic condition affecting certain populations. Genetic testing can identify those at risk before starting a fava bean diet.

In conclusion, both velvet and fava beans show promise as dietary adjuncts in managing Parkinson’s disease, particularly in low-income areas where access to medications is limited. However, they should not replace established treatments without further research and clinical guidance.